Dry powder inhalant of interferon alpha
A dry powder inhaler and interferon α technology, which is applied in antiviral agents, medical preparations containing active ingredients, peptide/protein components, etc., can solve the problems of increasing the complexity and cost of the preparation process, the stability of dry powder inhalers, and the use of performance impact etc.
Image
Examples
Embodiment 1
[0030] Embodiment 1: the preparation of the dry powder inhalation of interferon alpha
[0031] Prepare each solution for spray drying according to the formula in Table 1 below, and then use Buchi B-290 spray dryer to spray dry according to the following conditions: spray drying air inlet temperature 120 ° C, spray drying air flow rate 500 L / h, spray liquid flow rate 5ml / min, spray liquid temperature 8°C, keep spray drying gas inlet temperature and flow rate for 20 minutes after all liquid spray is completed.
[0032] Table 1 Prepare the solution formula (1000ml) for spray drying of the dry powder inhaler of interferon α
[0033]
Embodiment 2
[0034] Embodiment 2: the quality evaluation of the dry powder inhaler particle of interferon alpha
[0035] According to the provisions of the "Chinese Pharmacopoeia 2010 Edition (Part Three)" appendix "Interferon Biological Activity Assay Method", the activity of interferon α in the solution after the dissolution of the prepared interferon α dry powder inhalation particles of each formula (IU / ml); According to the provisions of the second method Lowry method of "Protein Content Determination Method" in the appendix of "Chinese Pharmacopoeia 2010 Edition (Part Three)", the interferon α in the solution of the prepared interferon α dry powder inhalation particles of each formula was determined after dissolution The concentration (mg / ml) was divided by the two to obtain the specific activity (IU / mg) of interferon α in the prepared interferon α dry powder inhalation particles of each formula. The specific activity of interferon α in each solution for spray drying was measured by ...
Embodiment 3
[0041] Embodiment 3: the in vitro deposition test of the dry powder inhalation of interferon alpha
[0042] A part of the dry powder inhalation sample of interferon alpha of each formula obtained by the method of Example 1 is subpackaged with the amount of 20 mg per capsule, respectively, to obtain non-loaded body capsule subpackage samples of formula 1-12; Mix evenly with commercially available large-size lactose carrier granules at a mass ratio of 1:2, and subpackage in an amount of 20 mg per capsule to obtain loading capsule subpackage samples of formulas 1-12. For formula 1-12, the unloaded capsule subpackage samples and the loaded capsule subpackage samples were respectively according to the "Chinese Pharmacopoeia 2010 Edition (Part Two)" appendix "Appendix X H inhalation gas (powder) aerosol effective part drug deposition method "Determination of in vitro deposition properties. The secondary deposits were weighed and completely dissolved respectively, and then the conce...
PUM
| Property | Measurement | Unit |
|---|---|---|
| particle size | aaaaa | aaaaa |
| particle size | aaaaa | aaaaa |
| particle size | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- IPC
- A61K9/72; A61K38/21; A61P31/12
- Inventors
- 周敏毅; 刘金毅
